Navigation Links
Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
Date:4/23/2008

e was dollar-denominated. Excluding the impact of the stronger yen, Aflac Japan's net investment income rose 5.1%. Due to the continued improvement in the benefit ratio, the pretax operating profit margin expanded from 17.6% to 18.0%. As a result, pretax operating earnings in yen were up 4.8%. Adjusting for the impact of the stronger yen on Aflac Japan's dollar-denominated investment income, pretax earnings rose 10.6%.

The average yen/dollar exchange rate in the first quarter of 2008 was 105.06, compared with an average rate of 119.48 in the first quarter of 2007. Aflac Japan's growth rates in dollar terms were significantly enhanced as a result of the 13.7% strengthening of the average exchange rate during the quarter.

Total revenues were $3.1 billion, an increase of 16.6%. Premium income in dollars was $2.6 billion in the first quarter, up 17.7% over a year ago. Net investment income rose 13.7% to $496 million. Pretax operating earnings climbed 19.2% in the quarter to $554 million.

Aflac Japan produced better-than-expected sales in the first quarter. Total new sales increased 5.0% to 27.6 billion yen, or $264 million in the first quarter. We had anticipated that first quarter sales growth would be below our annual objective due primarily to an expected slow start in the recently opened bank channel. Bank channel sales were 276 million yen, or just 1% of total new sales in the first quarter. However, as the year progresses, we expect to see further sales gains in the bank channel. By April 1, 2008, 90 banks had agreed to offer our products to their customers. Sales in the quarter benefited from significant improvement in our stand-alone medical insurance sales. Medical sales were up 17.6% and reflected a strong contribution from Gentle EVER, our nonstandard medical product. We were also pleased with the growth of cancer insurance sales, which reflected the success of our new Cancer Forte product.

AFLAC U.S.

Aflac U.S. produced str
'/>"/>

SOURCE Aflac Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Aflac Incorporated To Release First Quarter Results on April 23, 2008
2. Aflac Named Among the 50 Best Companies for Supplier Diversity
3. Aflac Reaches $40 Million Milestone in Donations to the Aflac Cancer Center and Blood Disorders Service of Childrens Healthcare of Atlanta
4. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
5. Training Magazine Applauds Aflacs Employee Learning Programs
6. Aflac Incorporated Announces Fourth Quarter Results
7. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
8. Aflac to Sponsor Iron Girl
9. Aflac Incorporated to Present at the Goldman Sachs Financial Services CEO Conference 2007
10. Aflac Japan To Offer Cancer Insurance Product Through Japan Post
11. Aflac Honors Hispanic Entrepreneurs Making a Difference in Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Acceleratio Ltd., an innovative software development ... of Server Monitoring Toolkit , a web ... It brings real-time server monitoring via a live ... enhanced features that significantly improve troubleshooting and detection ... agentless data collection, a user-friendly interface, and many ...
(Date:9/17/2014)... 17, 2014 Lintelus, Inc., a ... it has released Lintelus Meeting Version 3.1, designed ... corporate events. The newest release includes features to ... management capabilities and allow a more personalized event ... Lintelus Meeting 3.1 offers product advancements including real-time ...
(Date:9/17/2014)... HERNDON, VIRGINIA (PRWEB) September 17, 2014 ... top rhinoplasty specialist surgeons, has been recognized as a recipient ... is reserved for only the best of the best as ... by specialty. , Dr. Naderi, who is affectionately known by ... of only a handful of true rhinoplasty specialist ...
(Date:9/17/2014)... Promising new research published in the ... on the potential ability of ketones to support brain ... The study shows that brain hypometabolism associated ... impaired glucose uptake and/or utilization, and results suggest that ... The study, by the Research Center on Aging and ...
(Date:9/17/2014)... TENN. September 16, 2014) A study led ... found the chemotherapy dose threshold below which male ... sperm production. The study appears in September 17 ... , By clarifying which patients are at highest ... expect the findings to eventually increase use of ...
Breaking Medicine News(10 mins):Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 2Health News:Vitals Honors Dr. Shervin Naderi With Top 10 Doctor Award 3Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3
... , , WEDNESDAY, Nov. 14 (HealthDay News) -- During a ... drugs to be sold by pharmacists without a prescription, ... for and against the proposal by representatives of various ... day,s end, the FDA officials said they weren,t ready ...
... a,statement from Jeff Levi, Executive Director of Trust ... (TFAH) urges Congress to override the,President,s veto of ... Agencies Appropriations bill., The Labor/HHS bill provides ... states, territories, localities and hospitals to prepare for,public ...
... Kalamazoo, Mich.-based,Stryker Corporation and its former outpatient ... pay the United States $16.6,million to settle ... and other federal health care programs, the ... allegations that Physiotherapy, which is based,in Memphis, ...
... announced today,that the U.S. Food and Drug ... beta) for the treatment of anemia,associated with ... patients,on dialysis and patients not on dialysis. ... (CKD). MIRCERA is the only FDA-approved,erythropoiesis-stimulating agent ...
... Conference Call Scheduled for November 20, NAPA, Calif., ... specialty life sciences company engaged in the,study of senescense, ... skincare,and dermatological therapeutics today announced financial results for the,quarter ... quarter 2007 were $469,000 compared to,$2,027,000 for the same ...
... Natural Nutrition,(OTC Bulletin Board: NNTN) ( http://www.naturalnutritioninc.com ) ... of 10-QSB. Chris Mathers, CFO of,Natural Nutrition said, ... filing for Natural Nutrition will not be filed ... record revenue of $12.644,million and record EBITDA of ...
Cached Medicine News:Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:Natural Nutrition to Report Record Revenue and EBITDA in Late Filing of 10-QSB 2
(Date:9/17/2014)... 17, 2014 Research and Markets ... Cancer Market 2014-2018" report to their offering. ... growth of cancerous cells in the breast tissue. It ... cancer is rare. Histologically, breast cancer can be classified ... undifferentiated carcinoma. Ductal carcinoma is the form of breast ...
(Date:9/16/2014)... , 17. September 2014 ... ), hat heute die Markteinführung des ... Probenverarbeitung, in Europa bekannt gegeben. Der ... Universalplattform zur Vereinfachung der präanalytischen Probenverarbeitung. ... und fehlerbehaftete Arbeitsschritte bei der manuellen ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Aspen® CTO combines highly effective immobilization of ... a level of comfort that makes it ... substantially progressive immobilization in going from a ... and then on to a four-post orthosis. ...
... Shoulder Immobilizer with Contoured ... Navy cotton sling with foam-padded ... body straps. Quick-release closure buckles. ... 35 covered abduction wedge to ...
The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
Medicine Products: